Recro Pharma Offers Phase III IV Meloxicam Efficacy Data In Patients Following Abdominoplasty: 30mg Showed 'Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics'